Cargando…
Mesenchymal stem cells and management of COVID-19 pneumonia
Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia associated with rapid virus replication. Arising in Wuhan China December 2019, the current COVID-19 epidemic has rapidly grown with person-to-person infection expanding to become a global health emergency now on pandemic scale. G...
Autor principal: | Metcalfe, Su M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147223/ https://www.ncbi.nlm.nih.gov/pubmed/32296777 http://dx.doi.org/10.1016/j.medidd.2020.100019 |
Ejemplares similares
-
Mesenchymal stem cells in the treatment of coronavirus-induced pneumonia (COVID-19)
por: Mazzeo, Angela, et al.
Publicado: (2020) -
Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
por: Leng, Zikuan, et al.
Publicado: (2020) -
Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia
por: Guo, Zhinian, et al.
Publicado: (2020) -
Nebulization Therapy with Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for COVID-19 Pneumonia
por: Chu, Meiping, et al.
Publicado: (2022) -
LIF and the lung’s stem cell niche: is failure to use LIF to protect against COVID-19 a grave omission in managing the pandemic?
por: Metcalfe, Su M
Publicado: (2020)